MOSCOW (Sputnik) - The Russian Federal Service for Surveillance in Healthcare (Roszdravnadzor) said on Friday that it had not received any reports about adverse reactions to the antiviral drug favipiravir, the possibility of which was previously reported by the information centre PharmaCOVID.
The information centre for the pharmacotherapy of COVID-19 patients has published a research paper claiming that favipiravir, which has produced positive results in a Phase 3 trial, may have a side effect causing movement disorders.
"According to the Pharmaconadzor 2.0 database of the automated information system of Roszdravnadzor, at the moment there have been no reports about the development of reactions associated with nonspecific motor disorders, including falls", a statement read.
The watchdog's press service added that drug manufacturers, as well as pharmacists and physicians, were obliged to inform Roszdravnadzor about any side effects and adverse reactions.
"Roszdravnadzor pays special attention to monitoring the safety of these medicinal products, and if there is a need to change the instructions for the medical use of these products, such changes will be made in accordance with current legislation", the watchdog noted.